Analyst Price Target is $16.50
▲ +11.94% Upside Potential
This price target is based on 5 analysts offering 12 month price targets for BELLUS Health in the last 3 months. The average price target is $16.50, with a high forecast of $20.00 and a low forecast of $14.75. The average price target represents a 11.94% upside from the last price of $14.74.
Current Consensus is
The current consensus among 5 investment analysts is to hold stock in BELLUS Health. This Hold consensus rating has held steady for over two years.
BELLUS Health Inc., a clinical-stage biopharmaceutical company, develops therapeutics for the treatment of refractory chronic cough (RCC) and other cough hypersensitivity indications. Its lead product candidate includes BLU-5937, an antagonist of the P2X3 receptor, which is in Phase II clinical trial for treatment of RCC and chronic pruritus. BELLUS Health Inc. was incorporated in 1993 and is based in Laval, Canada. As of June 28, 2023, BELLUS Health Inc. operates as a subsidiary of GSK plc.